Alnylam and Inceptive land up to $2 billion AI RNA deal
The pact could speed RNA drug discovery, showing how AI is becoming a core tool in biotech dealmaking, not just a lab experiment.
By Mohammed Al-Shehri·· 3 min
2 briefings · “biotech”
The pact could speed RNA drug discovery, showing how AI is becoming a core tool in biotech dealmaking, not just a lab experiment.
By betting on genomic data a decade ago, Amgen is now navigating the high-stakes tension between self-taught AI autodidacts and irreplaceable scientific experts.